Ordaos Bio
Ordaos Bio is a private, AI-native biotechnology company that uses a proprietary generative AI Design Engine to design de novo mini-proteins (miniPRO™) for pharmaceutical and biotech partners, targeting difficult-to-drug oncology and rare disease indications.
- Company typePrivate
- Founded2021
- HeadquartersManhattan, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Ordaos Bio does
Ordaos Bio is a privately held, AI-native biotechnology company that designs de novo mini-proteins for therapeutic drug discovery. The company's core product is the miniPRO™ platform — a class of mini-proteins (40–160 amino acids, roughly 20x smaller than monoclonal antibodies) engineered to combine antibody-like target specificity with improved thermostability, solubility, manufacturability, and the ability to penetrate disease microenvironments including tumors and the blood-brain barrier. Mini-proteins are generated by the Ordaos Design Engine, a proprietary multitask meta-learning model that combines generative AI and reinforcement learning on public and proprietary datasets. The engine generates, appraises, and ranks billions of candidate sequences and hundreds of thousands of structures against a client-defined molecular target product profile (mTPP), iterating via a continuous in silico-to-in vitro learning loop with the company's wet-lab at JLABS@NYC. Notable technical outputs include de novo HER2 binders produced within weeks and single-domain VHH antibodies against SARS-CoV-2 S1 with picomolar to sub-nanomolar binding affinity.
Ordaos operates as a B2B drug-design partner for pharmaceutical and biotechnology companies, monetizing through joint development agreements, research collaborations, and milestone-based programs rather than selling a standalone product. Its named partners are predominantly small-to-mid biotechs focused on difficult-to-drug oncology indications: NonExomics (three rare cancer targets, Sept 2022), Yatiri Bio (two AML targets, Dec 2022), FatiAbGen (pancreatic and ovarian cancer antibody optimization, Feb 2023), and a three-way collaboration with Vyant Bio and Cellaria (biomarker-specific small proteins, April 2021). The company also runs an internal pipeline focused on overlooked patient populations in triple-negative breast cancer, esophageal cancer, and AML. Go-to-market relies on direct enterprise partnerships supplemented by JLABS@NYC (Johnson & Johnson Innovation) infrastructure, AWS Generative AI Accelerator compute credits, and CRO relationships for productionized protein production.
The company is Delaware-incorporated (Ordaos, Inc.), headquartered in New York, NY, and has raised approximately $15M+ cumulatively across a 2020 pre-seed round, a $5M seed in August 2022 led by Middleland Capital's VTC Ventures, a $1.8M convertible note in September 2023, a $3.1M exempt securities offering in September 2024, and a smaller filing in April 2025. The leadership team combines pharma R&D experience (ex-GSK, ex-Rockefeller) with applied ML/AI pedigree (ex-DARPA, Pfizer, BOSCH), and the company maintains an active conference presence at BIO, PEGS, JPM Healthcare, and PMWC.
Ordaos Bio firmographics
Firmographics- Name
- Ordaos Bio
- Legal name
- Ordaos, Inc.
- Website
- https://ordaos.bio
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ordaos Bio is a private, AI-native biotechnology company that uses a proprietary generative AI Design Engine to design de novo mini-proteins (miniPRO™) for pharmaceutical and biotech partners, targeting difficult-to-drug oncology and rare disease indications.
- Ownership category
- akta.pro rank
Ordaos Bio industry classification
Industry- Product category
- AI-Driven Protein Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Ordaos Bio is headquartered
LocationHeadquarters
- HQ city
- Manhattan
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ordaos Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Partner Collaboration Agreements: Ordaos generates revenue through partnerships with pharma and biotech companies for drug design and discovery services, including joint development agreements and research collaborations to create novel therapeutics against specific targets.
- Joint Development Agreements: Collaborative agreements where Ordaos uses its Design Engine to create protein candidates while partners provide target identification and preclinical validation capabilities, with milestone-based development.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Ordaos Bio product offering
Product offeringCore offering
Ordaos Bio partners with pharmaceutical and biotechnology companies to design novel, de novo mini-proteins (miniPRO™, 40-160 amino acids) using its proprietary AI-driven Design Engine. The company offers both custom mini-protein design against client-specified molecular target product profiles and optimization of existing antibody programs, delivering therapeutic candidates intended to be smaller, more stable, and easier to manufacture than traditional monoclonal antibodies. Services are delivered through joint development agreements and research collaborations targeting difficult-to-drug diseases and overlooked patient populations.
Product overview
Ordaos Bio is a human-enabled, machine-driven drug design company offering a unified platform centered on two core offerings: the miniPRO™ mini-protein product line and the Ordaōs Design Engine technology platform. The Design Engine serves as the foundational technology that generates de novo mini-proteins, while miniPRO™ represents the actual therapeutic mini-protein products created using the platform. Together, these offerings enable pharma and biotech partners to design and deliver safer, more effective therapeutics in a fraction of the time required by traditional discovery methods.
Differentiator
Problem solved
Functional benefit
Brands
- miniPRO™: A class of mini-proteins (40-160 amino acids) that provide antibody-like power and performance while being more configurable, stable, and easier to manufacture. 20x smaller than traditional monoclonal antibodies.
Products and services
- miniPRO™ A class of de novo designed mini-proteins (40-160 amino acids) that deliver antibody-like binding and specificity while being more configurable, thermostable, soluble, and easier to manufacture than traditional monoclonal antibodies. Designed to penetrate disease microenvironments and address targets difficult for full-size antibodies, intended for pharmaceutical and biotechnology partners developing therapeutics in oncology and rare disease.
- Ordaōs Design Engine A multitask meta-learning platform that uses generative AI and reinforcement learning, trained on public and proprietary biological datasets, to design de novo mini-proteins from amino acids. Generates, appraises, and ranks billions of protein sequences and hundreds of thousands of protein structures against client-specified molecular target product profiles (mTPPs), optimizing simultaneously across structure, binding specificity and affinity, solubility, stability, immunogenicity, and developability. Delivered as a service to pharmaceutical and biotechnology partners.
- Custom Mini-Protein Design and Antibody Optimization Partnerships Engagement-based drug design services delivered through joint development agreements and research collaborations with pharma and biotech partners. Each engagement scopes a set of molecular targets or antibody optimization objectives, with Ordaos applying the Design Engine and miniPRO™ approach to generate, validate in vitro, and advance de novo protein candidates. Active engagements span difficult-to-drug oncology indications (triple-negative breast, pancreatic, ovarian, AML, esophageal) and rare cancers.
Quantifiable outcome
- miniPRO™ proteins are 93% smaller than standard of care HER2-targeting treatments
- +4 more outcomes
Companies that use Ordaos Bio
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Ordaos Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Ordaos Bio partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Johnson & Johnson Innovation - JLABScoreResidency at JLABS@NYC providing lab space, industry connections, entrepreneurial programs, and collaboration opportunities. The residency supports R&D optimization, enables in-house wet lab capabilities, and provides access to Johnson & Johnson's resources and expertise.
- AWS (Amazon Web Services)coreSelected for inaugural AWS Generative AI Accelerator cohort, receiving up to $300,000 in AWS credits, training, mentorship, technical guidance, and introductions to industry leaders and potential investors. AWS provides cloud infrastructure support for Ordaos' generative AI and protein design operations.
- FatiAbGencoreCollaboration to optimize monoclonal antibodies for challenging oncology conditions including pancreatic and ovarian cancer. Ordaos uses its in silico Design Engine to enhance safety and efficacy of FatiAbGen's existing monoclonal antibodies while FatiAbGen develops optimized antibodies in preclinical studies.
- Yatiri BiocoreJoint development agreement to create novel therapeutics for two novel targets in Acute Myeloid Leukemia (AML). Yatiri Bio identifies cell surface therapeutic targets using its proteomics platform while Ordaos creates de novo protein candidates using its Design Engine and conducts in vitro validation.
- NonExomicscoreResearch collaboration to develop miniPROs for three specific difficult-to-target rare cancers. Ordaos uses its Design Engine to generate and rank novel miniPRO candidates while NonExomics conducts preclinical certification to demonstrate commercial value. NonExomics leverages AI and proteogenomics to identify novel disease-associated biomarkers from non-conventional protein-coding regions.
- Vyant BiocoreThree-way collaboration to design and qualify biomarker-specific small protein therapeutics. Vyant Bio provides preclinical development expertise and regulatory readiness while Ordaos generates in silico protein sequences and Cellaria provides patient-specific cell models for testing.
- CellariacoreThree-way collaboration providing patient-specific cell models and in vitro tumor models for therapeutic evaluation. Cellaria's models are directly linked to patient disease states enabling genomic, proteomic, and combinatorial analysis for target validation.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Ordaos Bio competitors and assessment
Company assessmentDirect peers
- Generate Biomedicines: Flagship-backed generative AI platform for de novo protein therapeutics. Directly comparable to Ordaos's Design Engine approach of designing novel proteins in silico rather than discovering them, with a similar pharma partnership GTM and a focus on hard-to-drug targets.
- Cradle Bio: AI-driven protein design company serving biotech and pharma partners to engineer novel biologics, including enzymes and therapeutic proteins. Closely parallels Ordaos's B2B partnership model and generative protein design methodology.
- Profluent Bio: Uses large language models trained on biological sequences to design novel proteins de novo, including CRISPR-Cas variants and antibodies. Highly comparable technology stack and 'design from scratch' philosophy.
- Absci: AI-powered generative protein design platform with wet-lab validation for therapeutic antibodies and beyond. Comparable in combining in silico design with high-throughput wet-lab iteration, and also partners with pharma on de novo biologics.
- BigHat Biosciences: AI/ML-driven antibody design platform integrating wet-lab high-throughput characterization with generative models. Closely comparable to Ordaos in targeting antibody/mini-protein therapeutics through an integrated design-validate loop.
- Molecular Partners: Clinical-stage developer of designed ankyrin repeat proteins (DARPins), which are 40-160 amino acid mini-proteins functionally analogous to Ordaos's miniPROs. Most direct modality competitor, with validated clinical assets and pharma partnerships.
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction to therapeutic design. Represents the well-capitalized incumbent version of Ordaos's vision, with pharma partnerships (Eli Lilly, Novartis) and broader scope.
- Schrödinger: Public computational chemistry and biology platform serving pharma with molecular simulation, including protein design and predictive modeling. A larger, established player whose broader platform overlaps with Ordaos's in silico protein engineering capabilities.
- Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas. Operates at much larger scale than Ordaos but pursues adjacent AI-for-biologics-discovery territory.
Emerging players
- Adaptyv Bio: Early-stage AI protein engineering company focused on automated wet-lab validation of designed proteins. Overlaps with Ordaos in generative protein design but at smaller scale and more focused on tooling/infrastructure.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Ordaos Bio social profiles
Digital presenceOrdaos Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ordaos Bio leadership team
Management profileNumber of profiles
Profiles5 records
Ordaos Bio funding detail
Funding detailFunding overview
Funding rounds7 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ordaos Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ordaos Bio
What does Ordaos Bio do?
Ordaos Bio partners with pharmaceutical and biotechnology companies to design novel, de novo mini-proteins (miniPRO™, 40-160 amino acids) using its proprietary AI-driven Design Engine. The company offers both custom mini-protein design against client-specified molecular target product profiles and optimization of existing antibody programs, delivering therapeutic candidates intended to be smaller, more stable, and easier to manufacture than traditional monoclonal antibodies. Services are delivered through joint development agreements and research collaborations targeting difficult-to-drug diseases and overlooked patient populations.
Is Ordaos Bio a public or private company?
Ordaos Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ordaos Bio founded?
Ordaos Bio was founded in 2021. It employs 11 to 50 people.
Where is Ordaos Bio based?
Ordaos Bio is headquartered in Manhattan, United States, in the North America region.
How does Ordaos Bio make money?
Two revenue lines are on record. Partner Collaboration Agreements are the primary driver. The others are joint Development Agreements.
Who are Ordaos Bio's main competitors?
Direct peers on record are Generate Biomedicines, Cradle Bio, Profluent Bio, Absci, BigHat Biosciences and Molecular Partners. Broad incumbents are Isomorphic Labs, Schrödinger and Recursion Pharmaceuticals. Adaptyv Bio is listed as an emerging player.
Does Ordaos Bio have an API?
No public API is recorded for Ordaos Bio.
What industry is Ordaos Bio in?
Ordaos Bio's product category is AI-Driven Protein Drug Discovery. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.